GoHealth (GOCOQ) EBITDA (2019 - 2026)

GoHealth (GOCOQ) has 8 years of EBITDA data on file, last reported at -$34.8 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 621.73% year-over-year to -$34.8 million; the trailing twelve-month figure through Mar 2026 stood at -$454.4 million (down 12534.7% YoY), and the FY2025 full-year result was -$412.9 million, down 5759.25% from the prior year.
• EBITDA slipped to -$34.8 million in Q1 2026, from -$32.3 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $80.3 million in Q4 2024 to a low of -$287.9 million in Q3 2025.
• A 5-year average of -$50.3 million and a median of -$38.0 million in 2023 frame the typical range for EBITDA.
• Across the five-year window, EBITDA sank 1894.89% in 2022 and surged 432.98% in 2024, its largest moves.
• Tracing GOCOQ's EBITDA over 5 years: stood at -$133.2 million in 2022, then soared by 111.31% to $15.1 million in 2023, then surged by 432.98% to $80.3 million in 2024, then slumped by 140.2% to -$32.3 million in 2025, then slipped by 7.83% to -$34.8 million in 2026.
• Business Quant data shows GOCOQ's EBITDA at -$34.8 million in Q1 2026, -$32.3 million in Q4 2025, and -$287.9 million in Q3 2025.